2019
Peer Influence on Physician Use of Shorter Course External Beam Radiation Therapy for Patients with Breast Cancer
Yu JB, Pollack CE, Herrin J, Soulos PR, Zhu W, Xu X, Gross CP. Peer Influence on Physician Use of Shorter Course External Beam Radiation Therapy for Patients with Breast Cancer. Practical Radiation Oncology 2019, 10: 75-83. PMID: 31785370, PMCID: PMC7061062, DOI: 10.1016/j.prro.2019.11.001.Peer-Reviewed Original ResearchConceptsAdjuvant external beam radiation therapyExternal beam radiation therapyPhysician peer groupsPalliative external beam radiation therapyBeam radiation therapyBreast cancerAdjuvant therapyBone metastasesPatient receiptRadiation therapyBreast-conserving surgeryMixed-effects logistic regressionPatient-sharing relationshipsPalliative therapyCancer careMedicare beneficiariesPatientsPhysician useTherapyLogistic regressionShort courseCancerPhysiciansGroup rateMetastasis
2018
Persistent Use of Extended Fractionation Palliative Radiation Therapy for Medicare Beneficiaries with Metastatic Breast Cancer: 2011-2014
Yu J, Pollack C, Herrin J, Zhu W, Soulos P, Xu X, Gross C. Persistent Use of Extended Fractionation Palliative Radiation Therapy for Medicare Beneficiaries with Metastatic Breast Cancer: 2011-2014. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e425. DOI: 10.1016/j.ijrobp.2018.07.1241.Peer-Reviewed Original Research
2015
The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer
Xu X, Herrin J, Soulos PR, Saraf A, Roberts KB, Killelea BK, Wang SY, Long JB, Wang R, Ma X, Gross CP. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Services Research 2015, 51: 167-186. PMID: 26119176, PMCID: PMC4722219, DOI: 10.1111/1475-6773.12328.Peer-Reviewed Original ResearchConceptsBreast cancer careHospital referral regionsCancer careMedicare expendituresBreast cancerRadiation therapyTreatment factorsMean Medicare expendituresEnd Results-MedicareSpecific treatment modalitiesContribution of patientCost of careHighest spending quintilePatient factorsTreatment patternsTumor characteristicsCancer characteristicsTreatment modalitiesReferral regionsMedicare beneficiariesQuintilePatientsCancerCareTherapyOlder Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods
Feinstein AJ, Long J, Soulos PR, Ma X, Herrin J, Frick KD, Chagpar AB, Krumholz HM, Yu JB, Ross JS, Gross CP. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs 2015, 34: 592-600. PMID: 25847641, DOI: 10.1377/hlthaff.2014.1119.Peer-Reviewed Original ResearchConceptsStage II diseaseStage III diseaseCancer-related costsCancer careBreast cancerMedian costSurvival rateEnd Results Program-MedicareFive-year survivalCancer care costsBreast surgerySurvival outcomesImproved outcomesOlder womenRadiation therapyCare costsStage IIDiseaseStudy periodWomenCancerCareSignificant national attentionOutcomesPercent
2014
Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity
Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity. Journal Of Clinical Oncology 2014, 32: 1195-1201. PMID: 24616315, PMCID: PMC3986382, DOI: 10.1200/jco.2013.53.8652.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyIntensity-modulated radiation therapyGU toxicityIMRT patientsRadiation therapyTreatment initiationProstate cancerTreatment costsSBRT patientsMedicare beneficiaries ageBody radiation therapyMean treatment costProstate cancer treatmentRandom-effects modelUrinary incontinenceBiologic doseRandomized trialsRetrospective studyPrimary treatmentLower treatment costsBeneficiaries agePatientsMedicare programRadiation therapy treatmentProspective correlationStereotactic body radiosurgery versus intensity modulated radiotherapy for prostate cancer: Comparison of toxicity.
Yu J, Cramer L, Herrin J, Soulos P, Potosky A, Gross C. Stereotactic body radiosurgery versus intensity modulated radiotherapy for prostate cancer: Comparison of toxicity. Journal Of Clinical Oncology 2014, 32: 89-89. DOI: 10.1200/jco.2014.32.4_suppl.89.Peer-Reviewed Original ResearchStereotactic body radiosurgeryGU complicationsProstate cancerSBRT patientsIMRT patientsGU toxicityRate of complicationsRetrospective observational studyBladder outlet obstructionHigh cure ratesRandom-effects modelCost of treatmentOutlet obstructionUrinary incontinenceTreatment initiationRetrospective studyCure rateUrethral strictureDiagnosis codesPrimary treatmentObservational studyRadiation therapyMean costMedicare beneficiariesPatients
2013
For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery
Sen S, Soulos PR, Herrin J, Roberts KB, Yu JB, Lesnikoski BA, Ross JS, Krumholz HM, Gross CP. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery 2013, 155: 776-788. PMID: 24787104, PMCID: PMC4008843, DOI: 10.1016/j.surg.2013.12.009.Peer-Reviewed Original ResearchConceptsHospital ownership statusBreast-conserving operationsBreast-conserving surgeryUse of brachytherapyRadiation therapyOperative careBreast cancerMedicare beneficiariesOverall useReceipt of brachytherapyAdjuvant radiation therapyInvasive breast cancerFemale Medicare beneficiariesGreater overall useYears of ageShort life expectancyRetrospective studyRT modalityProfit hospitalsExpensive modalityOlder womenBrachytherapy useBreast brachytherapyHospitalBrachytherapyVariation in Receipt of Radiation Therapy After Breast-conserving Surgery
Feinstein AJ, Soulos PR, Long JB, Herrin J, Roberts KB, Yu JB, Gross CP. Variation in Receipt of Radiation Therapy After Breast-conserving Surgery. Medical Care 2013, 51: 330-338. PMID: 23151590, PMCID: PMC3596448, DOI: 10.1097/mlr.0b013e31827631b0.Peer-Reviewed Original ResearchConceptsUse of RTShort life expectancyRadiation therapyBreast cancerLife expectancyPrimary surgeonStage I breast cancerEarly-stage breast cancerRadiation oncologist densityAdjuvant radiation therapyI breast cancerReceipt of radiationBreast-conserving surgeryImpact of physiciansHierarchical logistic regression modelsLogistic regression modelsLonger life expectancyLE patientsRetrospective cohortLE groupOlder womenPatientsTreatment ratesWomenCancer
2012
The Adoption of New Adjuvant Radiation Therapy Modalities Among Medicare Beneficiaries With Breast Cancer: Clinical Correlates and Cost Implications
Roberts KB, Soulos PR, Herrin J, Yu JB, Long JB, Dostaler E, Gross CP. The Adoption of New Adjuvant Radiation Therapy Modalities Among Medicare Beneficiaries With Breast Cancer: Clinical Correlates and Cost Implications. International Journal Of Radiation Oncology • Biology • Physics 2012, 85: 1186-1192. PMID: 23182396, PMCID: PMC3606652, DOI: 10.1016/j.ijrobp.2012.10.009.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyRadiation therapy modalitiesRadiation therapy costsBreast cancerRadiation therapyTherapy modalitiesTherapy costsBrachytherapy useRadiation oncologistsEnd Results-Medicare databaseConventional external beam radiation therapyAdoption of intensityBreast-conserving surgeryRadiation therapy useUse of IMRTBeam radiation therapyNewer radiation therapy modalitiesHierarchical logistic regressionHospital-based facilitiesTherapy useClinical factorsClinical correlatesTreatment optionsTreatment choicePhysician preferenceProton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation Therapy
Yu J, Soulos P, Herrin J, Cramer L, Potosky A, Roberts K, Gross C. Proton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s13. DOI: 10.1016/j.ijrobp.2012.07.040.Peer-Reviewed Original ResearchProton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.
Yu J, Soulos P, Cramer L, Roberts K, Herrin J, Potosky A, Gross C. Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. Journal Of Clinical Oncology 2012, 30: 4651-4651. DOI: 10.1200/jco.2012.30.15_suppl.4651.Peer-Reviewed Original ResearchProstate cancer patientsSix monthsShort-term toxicityOne-yearCancer patientsPRT patientsProstate cancerProton radiotherapyLogistic regressionTreatment-related complicationsOne-year outcomesCumulative complication rateMultivariable logistic regressionPatient-reported outcomesPatterns of careConditional logistic regressionHigher socioeconomic statusGU complicationsGU toxicityComplication rateEarly toxicityDiagnosis codesLong-term effectsRadiation therapyMedicare populationAssessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice